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Summary
Since publication of the initial guidelines for the prevention
of group B streptococcal disease in 1996, the incidence of
perinatal infection has decreased significantly. Intrapartum
antibiotic prophylaxis together with appropriate manage-
ment of neonates at increased risk for early-onset sepsis not
only reduces morbidity and mortality, but also decreases
the burden of unnecessary or prolonged antibiotic therapy.
This article provides healthcare workers in Switzerland
with evidence-based and best-practice derived guidelines
for the assessment and management of term and late pre-
term infants (>34 weeks) at increased risk for perinatal
bacterial infection. Management of neonates at increased
risk for early-onset sepsis depends on clinical presentation
and risk factors. Asymptomatic infants with risk factors
for early-onset sepsis should be observed closely in an in-
patient setting for the first 48 hours of life. Symptomatic
neonates must be treated promptly with intravenous antibi-
otics. As clinical and laboratory signs of neonatal infection
are nonspecific, it is mandatory to reevaluate the need for
continued antibiotic therapy after 48 hours.
Key words: Prevention; neonatal early-onset sepsis; group
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Introduction
Guidelines for the prevention of perinatal group B strepto-
coccal (GBS) disease were initially published in the USA
in 1996. They have been revised several times, most re-
cently in 2010 [2]. Since publication of the original
* This article is based on a publication in Paediatrica 2013;24:12‒5.
guidelines, the incidence of perinatal GBS disease has de-
creased significantly in the USA [2, 3]. In addition, intra-
partum antibiotic prophylaxis showed a beneficial effect
in reducing the incidence of perinatal infection in other
high-risk conditions (chorioamnionitis, prolonged rupture
of membranes) [4].
The mortality rate for GBS sepsis ranges from 4% to 11%
for term infants and is much higher for preterm infants
[2, 3]. The incidence of proven (culture positive) neonatal
early-onset sepsis, defined as onset of symptoms during the
first 3 days of life, is 0.76–0.9 per 1000 live births [3, 5].
As a result of false negative culture results the actual incid-
ence is probably higher. GBS is a major cause of early-on-
set sepsis, accounting for 38%–50% of perinatal bacterial
infections [3, 5, 6]. Implementation of GBS screening pro-
grammes during pregnancy and intrapartum prophylaxis of
GBS-positive mothers has led to an important reduction in
the incidence of GBS-related sepsis. Consequently, the pro-
portion of early-onset sepsis due to other bacteria such as
gram-negative bacilli has increased. Therefore, it is import-
ant to formulate recommendations for the care of infants at
risk of perinatal infection that do not only focus on GBS.
Our position is in line with the new guidelines of the Amer-
ican Academy of Pediatrics (AAP) published in 2011 and
2012 [7, 8]. In addition, updated guidelines from Australia
and New Zealand [9], and from the United Kingdom [10]
were published recently.
Swiss Guidelines for the management of neonates whose
mothers are colonised with GBS were published in 2001.
Recent data and the 2010 revised CDC guidelines promp-
ted the Swiss Society of Neonatology to commission a re-
vision of the 2001 paper. In a first meeting in December
2011, members of the task force analysed and discussed
guidelines and clinical studies published after 2001. The
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goal of the meeting was to identify topics that need to
be reconsidered and potentially changed. Recently pub-
lished guidelines and a focused literature search were used
to evaluate and discuss new data that support each re-
commendation. As maternal GBS colonisation is not the
only relevant risk factor for neonatal early-onset sepsis,
the guidelines have been broadened to include the manage-
ment of all neonates at increased risk for bacterial sepsis.
In December 2012, the new guidelines were discussed in-
dependently within the Paediatric Infectious Disease Group
of Switzerland and the Swiss Society of Neonatology and
finally approved early 2013. The recommendations were
previous published in the official Journal of the Swiss So-
ciety of Paediatrics, a nonpeer-reviewed and nonindexed
journal written in German/French for members of the
Swiss Society of Paediatrics [1]. This article is a modified
version of the previous publication.
Purpose of the guidelines
The aim of this guideline is to assist healthcare workers
providing care for neonates in the assessment and manage-
ment of neonates at increased risk for early-onset sepsis.
The goal is to prevent early-onset sepsis, to facilitate an
early diagnosis and to avoid unnecessary or prolonged an-
tibiotic therapy. Generally, preterm infants younger than
34–35 weeks gestation need special care and are hospital-
ised in neonatology units, and are therefore not discussed
in these guidelines. This guideline focuses on term and late
preterm infants (>34 weeks gestation) at risk for early-on-
set bacterial infection.
Management of neonates at increased
risk for infection
The management of neonates at increased risk for infection
depends on clinical presentation and underlying risk factors
(fig. 1). The clinical signs of neonatal infection are often
nonspecific and may be very subtle or even absent initially
(table 1). Therefore, the assessment of risk factors for
neonatal infection is crucial (table 2). In a prospective co-
hort study in an obstetric department in Switzerland, pre-
valence rate of GBS colonisation was 16.3% [11].
It is important to note that although intrapartum antibiotic
prophylaxis has been shown to decrease the incidence of
early-onset sepsis due to group B streptococcus, it does not
eliminate the risk for neonatal infection entirely. Therefore,
neonates born to mothers who meet the requirements for
intrapartum antibiotic prophylaxis need to be closely ob-
served for 48 hours postnatally [2, 7]. Over 90% of new-
born infants with perinatally acquired bacterial infection
will develop symptoms within the first 24–48 hours, em-
phasising the importance of this observation period [8, 12,
13]. If intrapartum prophylaxis is indicated but not admin-
istered, or administered less than 4 hours before delivery,
newborns are considered at increased risk of perinatal in-
fection and clinical observation is required, as for other risk
factors.
Newborn infants with clinical signs suggestive of
neonatal infection
The clinical signs of neonatal infection are diverse and non-
specific and may be missed (table 1). Clinical signs are
sensitive markers for neonatal infection, even when intra-
partum antibiotic prophylaxis was administered, but have a
low positive predictive value [2, 7–9, 12–14]. All newborn
infants with signs suggestive of neonatal infection need
empirical antibiotic treatment after blood cultures have
been drawn [2, 7–9].
The positive and negative predictive values of single dia-
gnostic laboratory tests are inadequate for early detection
of neonatal infection [8, 13, 15–19]. Therefore, diagnostic
laboratory tests cannot be used to decide whether antibi-
otics need to be started and a recommendation concern-
ing routine laboratory evaluation is not justified [8, 9].
Several publications have shown a high negative predictive
value for C-reactive protein (CRP) and procalcitonin (PCT)
determined during the course of treatment, which can be
used to stop empirically started antibiotic therapy early (see
below under “Length of antibiotic therapy for suspected
neonatal infection”) [15, 19–22].
Asymptomatic newborn infants with risk factors for
early-onset sepsis
Asymptomatic neonates with risk factors for early-onset
sepsis should be observed in an in-patient setting for the
first 48 hours of life. This entails 4-hourly monitoring of
vital signs (including temperature, peripheral perfusion and
Figure 1
Management of term and late preterm infants (>34 weeks) at
increased risk for neonatal bacterial infection (early-onset sepsis).
(1.) Tachypnoea, respiratory distress, apnoea, tachycardia/
bradycardia, poor peripheral perfusion, mottling, temperature
instability, lethargy, irritability, changes in tone, vomiting, poor
feeding.
(2.) Maternal group B streptococcus (GBS) colonisation (vaginal/
rectal swab: current or previous, bacteruria), preterm birth,
prolonged rupture of membranes >18 hours, chorioamnionitis
(maternal fever >38 °C plus two further symptoms: maternal
leucocytosis, foetal tachycardia, painful or tender uterus, fetid
amniotic fluid), required intrapartum prophylaxis missing or
inadequate.
(3.) Monitor vital signs every 4 hours: respiration, temperature,
peripheral perfusion, colour.
(4.) Elective Caesarean section (no rupture of membranes or
contractions): no postnatal observation of baby necessary
(regardless of maternal GBS status).
(5.) If there are coexisting risk factors and/or the baby has clinical
signs, discuss indication for laboratory tests with responsible
neonatologist.
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colour) by appropriately qualified staff. An effective in-
trapartum prophylaxis for GBS colonisation reduces but
does not eliminate the risk of GBS infection [2, 7]. The
risk of neonatal infection after an elective Caesarean sec-
tion (no contractions or rupture of membranes) is minimal
regardless of maternal GBS status, and thus both intra-
partum prophylaxis and postnatal observation of the infant
are not indicated [2, 7–9]. Contrary to the revised CDC re-
commendations, we do not recommend empirical antibiot-
ic therapy for asymptomatic neonates whose mothers have
signs of chorioamnionitis [2]. We recommend close obser-
vation for the first 48 hours, as for asymptomatic neonates
with other risk factors for infection. This management is
in agreement with the recent recommendations from Aus-
tralia and New Zealand as well as the AAP 2012 guidelines
for the management of neonates at increased risk for early-
onset sepsis [8, 9]. The risk of neonatal infection increases
with the number of coexisting risk factors and is highest
for term infants of GBS positive mothers with chorioam-
nionitis [8]. Relevant clinical information should always
be obtained from obstetricians and midwives. The indica-
tion for diagnostic tests (complete blood count, acute phase
reactants) and empirical antibiotic therapy should be dis-
cussed with the responsible neonatologist. Close observa-
tion is mandatory.
Asymptomatic neonates with unknown maternal GBS
status
If the GBS status is unknown at delivery (screening not
performed or results unavailable), intrapartum antibiotic
prophylaxis should be given and the infant should be mon-
itored for 48 hours postnatally if other risk factors for
neonatal infection are present (preterm birth <37 weeks,
prolonged rupture of membranes >18 hours, signs of chori-
oamnionitis) [2, 7]. Based on the high recurrence rate of
GBS colonisation, it is advisable to consider previous GBS
colonisation as a risk factor for neonatal infection (e.g. in
an earlier pregnancy) [23, 24].
Table 1: Clinical signs of early-onset sepsis.
(1.) Tachypnoea, respiratory distress, apnoea
(2.) Tachycardia/bradycardia, poor peripheral perfusion (i.e. capillary
refill time >3 seconds), mottling
(3.) Temperature instability (hyperthermia >38.0 °C or hypothermia
<36.0 °C)
(4.) Lethargy, irritability, altered muscular tone or floppiness
(5.) Vomiting, poor feeding
Table 2: Risk factors for early onset neonatal sepsis.
(1.) Maternal group B Streptococcus colonisation (vaginal/rectal
swab), bacteriuria or infection in the current pregnancy
(2.) Signs of chorioamnionitis (maternal fever >38 °C plus at least
two of the following symptoms: maternal leucocytosis (>15 G/l),
foetal tachycardia (>160/min), uterine tenderness, foul-smelling
amniotic fluid)
(3.) Prolonged rupture of membranes (>18 hours before delivery)
(4.) Preterm birth <37 weeks
(5.) Previous neonate with an invasive group B streptococcus
infection
(6.) Suspected infection in a sibling in the case of a multiple
pregnancy
Specific recommendations for
antibiotic therapy
Maternal antibiotic prophylaxis
Maternal antibiotic prophylaxis is the responsibility of the
attending obstetrician. Penicillin or amoxicillin are the an-
tibiotics of choice for intrapartum GBS prophylaxis [7–10].
Erythromycin is no longer recommended owing to a pre-
valence of GBS resistance of 30% [11]. Cefazolin, which
has similar pharmacokinetics to penicillin, is the antibiotic
of choice for women with a known penicillin allergy and
low risk of anaphylaxis. Vancomycin is recommended for
women with penicillin allergy and high risk of anaphylaxis,
whereas clindamycin is no longer recommended owing to
a prevalence of GBS resistance of 25–30% [11]. Effect-
ive and adequate antibiotic prophylaxis is defined as in-
trapartum prophylaxis with penicillin, amoxicillin or ce-
fazolin given at least 4 hours prior to delivery. There are
limited data on the efficacy and pharmacokinetics of van-
comycin [2].
Culture work-up of symptomatic neonatal infection
Blood cultures are mandatory in the work-up of sympto-
matic neonatal infection. The blood culture should be ob-
tained before antibiotics are given and at least 1 ml blood
should be drawn [8, 25]. The indication for a lumbar punc-
ture is controversial [2, 7]. A lumbar puncture should al-
ways be performed if blood cultures are positive and/or in
critically ill newborns. It should be borne in mind that cases
of neonatal meningitis have been documented with neg-
ative blood cultures [8, 26]. Antibiotics can be started at
meningitic doses to ensure adequate treatment of possible
meningitis (amoxicillin 200 mg/kg/day instead of 100 mg/
kg/day). The decision not to perform a lumbar puncture is
always an active one, and should be documented in the pa-
tient chart. If there is doubt about the indication, the lumbar
puncture can still be performed 1‒2 days after onset of the
infection and treatment [8]. Urine cultures, gastric aspirates
and body surface cultures have no place in the work-up of
early-onset sepsis.
Antibiotic therapy for suspected neonatal infection
An aminoglycoside (amikacin or gentamicin) combined
with amoxicillin given intravenously is the standard empir-
ic therapy. Appropriate doses for neonates within the first
week of life are: gentamicin 4–5 mg/kg/dose or amikacin
15 mg/kg/dose intravenously every 24 hours and amox-
icillin 50–100 mg/kg/dose intravenously every 12 hours.
There is a need for therapeutic drug monitoring for
aminoglycoside therapy. Cephalosporins should be avoided
as first-line therapy because of the high risk of developing
resistance and should be restricted to special cases [8, 27,
28].
Length of antibiotic therapy for suspected neonatal
infection
As the clinical and laboratory signs of neonatal infection
are nonspecific and symptomatic neonates are treated em-
pirically with antibiotics, it is important to reevaluate the
need for continued antibiotic therapy after 48 hours. In
most cases, based on the clinical course, negative culture
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results and laboratory parameters, a decision can be made
to stop safely antibiotic therapy after this time [8, 15,
19–22]. The frequent observation that prolonged antibiotic
therapy (>5 days) causes increased mortality and a higher
incidence of necrotising enterocolitis in preterm infants
emphasises the need to stop empirical antibiotic therapy in
the absence of proven infection (negative culture and neg-
ative acute phase reactants) as early as possible and at the
latest after 48–72 hours [29–31].
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Figures (large format)
Figure 1
Management of term and late preterm infants (>34 weeks) at increased risk for neonatal bacterial infection (early-onset sepsis).
(1.) Tachypnoea, respiratory distress, apnoea, tachycardia/bradycardia, poor peripheral perfusion, mottling, temperature instability, lethargy,
irritability, changes in tone, vomiting, poor feeding.
(2.) Maternal group B streptococcus (GBS) colonisation (vaginal/rectal swab: current or previous, bacteruria), preterm birth, prolonged rupture of
membranes >18 hours, chorioamnionitis (maternal fever >38 °C plus two further symptoms: maternal leucocytosis, foetal tachycardia, painful or
tender uterus, fetid amniotic fluid), required intrapartum prophylaxis missing or inadequate.
(3.) Monitor vital signs every 4 hours: respiration, temperature, peripheral perfusion, colour.
(4.) Elective Caesarean section (no rupture of membranes or contractions): no postnatal observation of baby necessary (regardless of maternal
GBS status).
(5.) If there are coexisting risk factors and/or the baby has clinical signs, discuss indication for laboratory tests with responsible neonatologist.
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